GREY:IMVIF - Post by User
Post by
antisenseon Feb 25, 2020 9:54am
337 Views
Post# 30730228
NOT impressive results
NOT impressive results I think we all need to check our egos (mine included) these were not impressive results. In fact if you had listened to the conference call you would see that this trial was really a waste of time.
Long terms holders would recall when Incyte pulled their drug Epacadostat from all trials. This really set back IMV and we seeing shadows of that today. This trial was the leftover from that epic failure. If you see the latest presentation you'll see that the arm 1 patients that received low dose Epacado achieved far GREATER results than anything DPX could produce alone. The crazy part is that when you incrased the Epacado dose to 300 you saw negative impacts and an undoing of the clinical benefit.
I think it was a mistake to remove low dose Epacadostat from the trial. It really had some great results. Our only hope now is to put this Incyte boondoggle behind us and wait for some real results with the Merck trials. I mean why even put the Incyte results in there just to rub it in investors faces what COULD have been....Maybe Incyte will come knocking on our door again...*sigh